BioAge Labs, Inc.
BIOA
$10.60
$0.171.63%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.45M | 2.77M | 3.08M | 2.05M | 2.41M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.45M | 2.77M | 3.08M | 2.05M | 2.41M |
| Cost of Revenue | 24.37M | 20.41M | 24.50M | 18.51M | 19.84M |
| Gross Profit | -21.91M | -17.64M | -21.42M | -16.46M | -17.43M |
| SG&A Expenses | 7.42M | 7.74M | 7.00M | 6.68M | 7.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.78M | 28.15M | 31.50M | 25.19M | 27.18M |
| Operating Income | -29.33M | -25.38M | -28.42M | -23.14M | -24.77M |
| Income Before Tax | -26.10M | -22.25M | -25.94M | -20.17M | -21.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.10M | -22.25M | -25.94M | -20.17M | -21.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.10M | -22.25M | -25.94M | -20.17M | -21.56M |
| EBIT | -29.33M | -25.38M | -28.42M | -23.14M | -24.77M |
| EBITDA | -29.26M | -25.31M | -28.35M | -23.09M | -24.71M |
| EPS Basic | -0.58 | -0.52 | -0.72 | -0.56 | -0.60 |
| Normalized Basic EPS | -0.36 | -0.33 | -0.45 | -0.35 | -0.38 |
| EPS Diluted | -0.58 | -0.52 | -0.72 | -0.56 | -0.60 |
| Normalized Diluted EPS | -0.36 | -0.33 | -0.45 | -0.35 | -0.38 |
| Average Basic Shares Outstanding | 44.84M | 42.48M | 36.18M | 35.85M | 35.85M |
| Average Diluted Shares Outstanding | 44.84M | 42.48M | 36.18M | 35.85M | 35.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |